AB-452
AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2226178-35-2
- 分子式: C21H26N2O6
- 分子量:402.44
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBeAg level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBeAg level measured after 16 days by ELISA
|
[PMID: 38190324] |
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBsAg level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBsAg level measured after 16 days by ELISA
|
[PMID: 38190324] |
| Hepatocyte | EC50 |
3 nM
Compound: (S)-20; AB-452
|
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBV DNA level measured after 16 days by ELISA
Antiviral activity against AAV-Hepatitis B virus infected in human Primary hepatocyte assessed as reduction in HBV DNA level measured after 16 days by ELISA
|
[PMID: 38190324] |
| HepG2 2.2.15 | CC50 |
>50 μM
Compound: (S)-20; AB-452
|
Cytotoxicity against human HepG2.2.15 cells by Cell-titer Glo luminescent assay
Cytotoxicity against human HepG2.2.15 cells by Cell-titer Glo luminescent assay
|
[PMID: 38190324] |
| HepG2 2.2.15 | EC50 |
0.001 μM
Compound: (S)-20; AB-452
|
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay
|
[PMID: 38190324] |
化学情報
-
CAS 番号 2226178-35-2
-
分子量 402.44
-
分子式 C21H26N2O6
-
SMILES
CC([C@H]1N2C(C3=NC(OC)=C(OCCCOC)C=C3C1)=CC(C(C(O)=O)=C2)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)